New shot cuts bad cholesterol in asian heart patients

NCT ID NCT04765657

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called inclisiran in about 345 Asian patients who have heart disease or are at high risk and still have high LDL (bad) cholesterol despite taking statins. The goal is to see if inclisiran lowers LDL cholesterol more than a placebo over about 11 months, and to check its safety. Participants continue their usual diet and statins during the trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerotic cardiovascular disease Dyslipidemias Hypercholesterolemia hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERCHOLESTEROLEMIA

Contacts and locations

Locations

Novartis Investigative Site

Lanzhou, Gansu, 730030, China
Novartis Investigative Site

Foshan, Guangdong, 528000, China
Novartis Investigative Site

Guangzhou, Guangdong, 510080, China
Novartis Investigative Site

Shijiazhuang, Hebei, 050000, China
Novartis Investigative Site

Baotou, Inner Mongolia, 014040, China
Novartis Investigative Site

Hohhot, Inner Mongolia, 010017, China
Novartis Investigative Site

Nanjing, Jiangsu, 210008, China
Novartis Investigative Site

Nanjing, Jiangsu, 211166, China
Novartis Investigative Site

Nantong, Jiangsu, 226000, China
Novartis Investigative Site

Suzhou, Jiangsu, 215004, China
Novartis Investigative Site

Xuzhou, Jiangsu, 221003, China
Novartis Investigative Site

Changchun, Jilin, 130000, China
Novartis Investigative Site

Changchun, Jilin, 130021, China
Novartis Investigative Site

Jinan, Shandong, 250013, China
Novartis Investigative Site

Jinshan, Shanghai Municipality, 201508, China
Novartis Investigative Site

Taiyuan, Shanxi, 030002, China
Novartis Investigative Site

Xian, Shanxi, 710061, China
Novartis Investigative Site

Tianjin, Tianjin Municipality, 300121, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310014, China
Novartis Investigative Site

Beijing, 100034, China
Novartis Investigative Site

Beijing, 100039, China
Novartis Investigative Site

Beijing, 100050, China
Novartis Investigative Site

Beijing, 100191, China
Novartis Investigative Site

Shanghai, 200032, China
Novartis Investigative Site

Shanghai, 200040, China
Novartis Investigative Site

Shanghai, 200080, China
Novartis Investigative Site

Shanghai, 200120, China
Novartis Investigative Site

Tianjin, 300052, China
Novartis Investigative Site

Tianjin, 300140, China
Novartis Investigative Site

Xiamen, 361004, China
Novartis Investigative Site

Singapore, 119074, Singapore
Novartis Investigative Site

Singapore, 169609, Singapore
Novartis Investigative Site

Wŏnju, Gangwon-do, 26427, South Korea
Novartis Investigative Site

Incheon, Korea, 405 760, South Korea
Novartis Investigative Site

Seoul, Korea, 02841, South Korea
Novartis Investigative Site

Seoul, Korea, 03080, South Korea
Novartis Investigative Site

Seoul, Seoul, 06351, South Korea
Novartis Investigative Site

Seoul, South Korea, 110-746, South Korea
Novartis Investigative Site

Gwangju, 61469, South Korea
Novartis Investigative Site

Seoul, 03722, South Korea
Novartis Investigative Site

Seoul, 05505, South Korea
Novartis Investigative Site

Kaohsiung City, 80756, Taiwan
Novartis Investigative Site

Taipei, 10002, Taiwan
Novartis Investigative Site

Taipei, 11217, Taiwan
Novartis Investigative Site

Taipei, 11220, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.